Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 11/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 8/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 5/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL466934 | 1.00 | KMT2A (0.44) | KMT2AHTR2CCHRNA7HTR2AHTR1A | |
| SCHEMBL7315071 | 1.00 | KMT2A (0.44) | KMT2AHTR2CCHRNA7HTR2AHTR1A | |
| Hydrochloric Acid SCHEMBL467145 | 0.99 | KMT2A (0.43) | KMT2AHTR2CCHRNA7HTR2AHTR1A | |
| Hydrochloric Acid SCHEMBL8419734 | 0.99 | KMT2A (0.43) | KMT2AHTR2CCHRNA7HTR2AHTR1A | |
| Hydrochloric Acid SCHEMBL467146 | 0.99 | KMT2A (0.43) | KMT2AHTR2CCHRNA7HTR2AHTR1A | |
| Hydrochloric Acid SCHEMBL7311725 | 0.99 | KMT2A (0.43) | KMT2AHTR2CCHRNA7HTR2AHTR1A | |
| Sulfuric Acid SCHEMBL7308241 | 0.94 | KMT2A (0.43) | KMT2AHTR2CCHRNA7HTR2AHTR1A | |
| Sulfuric Acid SCHEMBL7308229 | 0.94 | KMT2A (0.43) | KMT2AHTR2CCHRNA7HTR2AHTR1A | |
| SCHEMBL7314254 | 0.93 | DRD2 (0.43) | CHRNA7HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL7309602 | 0.89 | HTR1A (0.41) | KMT2AHTR2CHTR1ADRD2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436938-B1 | ADMINISTERING A SIGMA RECEPTOR LIGAND IN COMBINATION WITH AN ANTIDEPRESSANT AGENT; ESPECIALLY FOR REFRACTORY DEPRESSION | PFIZER INC. | 2002-08-20 | — | — | US | claimed |
| US-20020099045-A1 | Combination treatment for depression | PFIZER PRODUCTS INC. | 2002-07-25 | — | — | US | claimed |
| EP-1224930-A1 | Combination of a SR inhibitor and sigma receptor ligand in the treatment ofdepression | Pfizer Products Inc. (US) | 2002-07-24 | — | — | EP | claimed |
| EP-2600863-B1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | ESTEVE LABOR DR (ES) | 2018-03-28 | — | — | EP | disclosed |
| EP-2646025-B1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | ESTEVE LABOR DR (ES) | 2017-03-15 | — | — | EP | disclosed |
| EP-2531191-B1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | ESTEVE LABOR DR (ES) | 2016-03-30 | — | — | EP | disclosed |
| EP-2571501-B1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | ESTEVE LABOR DR (ES) | 2016-03-02 | — | — | EP | disclosed |
| EP-2460519-A1 | Use of sigma ligands in bone cancer pain | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-06-06 | — | — | EP | disclosed |
| EP-2415471-A1 | Use of sigma ligands in opioid-induced hyperalgesia | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-02-08 | — | — | EP | disclosed |
| EP-2388005-A1 | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-11-23 | — | — | EP | disclosed |
| EP-2353598-A1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-08-10 | — | — | EP | disclosed |
| EP-0916656-B1 | A method for production of pyrrolidinone derivatives | SCHERING AG (DE) | 2003-09-10 | — | — | EP | disclosed |
| US-6555694-B1 | Reacting an aniline and cyclopropane-1,1-dicarboxylic acid; free of hydrogen-generating substance and moisture sensitive reagent; corrosion resistance; simplification; for piperazine derivatives used as central nervous system disorders | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-29 | — | — | US | disclosed |
| US-6436938-B1 | ADMINISTERING A SIGMA RECEPTOR LIGAND IN COMBINATION WITH AN ANTIDEPRESSANT AGENT; ESPECIALLY FOR REFRACTORY DEPRESSION | PFIZER INC. | 2002-08-20 | — | — | US | disclosed |
| EP-1224930-A1 | Combination of a SR inhibitor and sigma receptor ligand in the treatment ofdepression | Pfizer Products Inc. (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-0839805-B1 | Pyrrolidinone derivatives and their use as antipsychotic medicaments | SCHERING AG (DE) | 2001-10-04 | — | — | EP | disclosed |
| US-6207825-B1 | REACTING THE CORRESPONDING 3-CARBOXYPYRROLIDINONE COMPOUND IN THE PRESENCE OF FORMALDEHYDE | MITSUI CHEMICALS, INC. (JP) | 2001-03-27 | — | — | US | disclosed |
| US-5969138-A | ANTIPSYCHOTIC AGENTS | MITSUI CHEMICALS, INC. (JP) | 1999-10-19 | — | — | US | disclosed |
| EP-0916656-A2 | A method for production of pyrrolidinone derivatives | Mitsui Chemicals, Inc. (JP) | 1999-05-19 | — | — | EP | disclosed |
| EP-0839805-A1 | Pyrrolidinone derivatives and their use as antipsychotic medicaments | MITSUI TOATSU CHEMICALS, INC. (JP) | 1998-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099045-A1 | Combination treatment for depression | HTR5A, HTR1A, OPRL1 | KMT2A 3616/4885HTR2C 10/4885CHRNA7 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.